McGowan, Hood, Felder & Phillips, LLC, Wants to Warn You of New and Dangerous Defective Drug Alerts for Janumet and Incivek

New risks discovered for users of Janumet

McGowan, Hood, Felder & Phillips, LLC, Wants to Warn You of New and Dangerous Defective Drug Alerts for Janumet and Incivek

If you have taken Janumet for Type 2 diabetes or Incivek (Telaprevir) for hepatitis C, you may be at serious risk. This special report is intended for immediate release to anyone who has been prescribed these drugs.

Janumet is a combination of metformin and sitagliptin. It is prescribed orally for Type 2 diabetes suffers to control blood sugar. The drug was approved for sale in March of 2007, and has been possibly been linked to pulmonary fibrosis. Pulmonary fibrosis causes scarring of the lung tissue, resulting in permanent disability or death.

Most people diagnosed with pulmonary fibrosis have a life expectancy of only 3-5 years. A devastating 86% of victims so far affected died after being diagnosed with pulmonary fibrosis. Worldwide sales of this commonly prescribed drug is about $6 billion per year; since its introduction to the market in 2007, it has made more than $40 billion for its manufacturer Merck.

If you are currently taking Janumet or have taken it in the past, seek medical attention immediately. The experienced South Carolina defective drug attorneys at McGowan, Hood, Felder & Phillips, LLC, can help you explore your options. Contact us immediately for a free consultation, or call 803-327-7800.

New risks associated with Incivek (Telaprevir)

Incivek is prescribed to manage the effects of the hepatitis C virus. The drug was approved for sale in 2011, and came with a side-effect warning for anemia. The drug was discontinued in October of 2014, but diagnosis of former users with aplastic anemia has continued to increase.

Aplastic anemia is a serious blood disorder that affects the body’s ability to produce new blood cells. Diagnosis of severe or acute aplastic anemia has a survivability rate of only 20% after two years. Aplastic anemia is a not a known side effect of any hepatitis virus, and the condition has been strongly linked to Incivek.

If you have taken Incivek (Telaprevir) to manage your hepatitis C symptoms, you may be at serious risk. Seek medical attention immediately. If you were diagnosed with aplastic anemia after taking this drug, you may be entitled to compensation. One of the experienced South Carolina defective drug lawyers at our firm can help.

What to do after taking a defective drug

If you were prescribed either of these drugs, or any other defective drug, you may be entitled to compensation for your health risk, treatment, and continuing care. The experienced and compassionate defective medical device attorneys at McGowan, Hood, Felder & Phillips, LLC, can help get you the compensation you deserve. Call 803-327-7800 or contact us today for a free consu